Israel Active

(Thanks to NoCamels.com) Israeli Shlomi Aflalo developed HelpAround, a crowdsourcing application for people with diabetes and other chronic diseases. It allows them to communicate and get immediate help from people in the vicinity.

(Thanks to Israel21c) Israel’s Orgenesis is a pioneer in the field of “cellular trans-differentiation”, a process to transform a type 1 diabetic patient’s own liver cells into new insulin-producing cells. Orgenesis is partnering with Belgium’s MaSTherCell to scale up development.

Globes “startup of the week” is Israel’s Endobetix with its implanted device that traps bile fluids and diverts them to another part of the intestine. The result is lower blood sugar without drugs or major surgery; hence no more diabetes.

Professor Eitan Kerem, MD, Chief of Pediatrics at Israel’s Hadassah University Medical Center, is the recipient of the prestigious 2014 European Cystic Fibrosis Society (ECFS) Award, for his research and contribution towards further understanding and treating the disease.

Hadassah’s Experimental School (HES) has been awarded Israel’s Ministry of Education “National Education Award”. HES serves children of all ages and backgrounds in the Jerusalem area, providing a unique taste of "healthy life".

EarlySense, developer and marketer of a hospital bed-monitoring device, has developed a chair to perform the same task. The chair monitors heart rate, respiration, and activity level. The product has now received US medical approval for marketing to hospitals in the USA.

(Thanks to NoCamels.com) Scientists at Israel’s GlassesOff have developed a proprietary method for improving near vision sharpness, by improving the image processing function in the visual cortex of the brain. A smartphone app can turn back the age clock of your eyes by over 8.5 years.

(Thanks to Nevet – www.broaderview.org) Ilan Dinstein, from Israel’s Ben-Gurion University, is using MRIs, DTIs and EEGs to transform the definition of autism from one that is behavioral to one that is biological.

Technion scientists have discovered that mutant gene UBB+1 is responsible for preventing the protein ubiquitin from marking other proteins for destruction. The proteins then are more likely to form the deadly plaque associated with Alzheimer’s disease.

Israel’s Itamar Medical manufactures the EndoPAT diagnostic device that measures how well your arteries are working. Japan’s Nihon Kohden will market EndoPAT to 100,000 doctors in Japan as its flagship product for monitoring the heart and blood vessels.